Neurotrophic effects of the peptide NAP: A novel neuroprotective drug candidate

Illana Gozes, Irit Spivak-Pohis

Research output: Contribution to journalShort surveypeer-review


This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.

Original languageEnglish
Pages (from-to)197-199
Number of pages3
JournalCurrent Alzheimer Research
Issue number3
StatePublished - 2006


Dive into the research topics of 'Neurotrophic effects of the peptide NAP: A novel neuroprotective drug candidate'. Together they form a unique fingerprint.

Cite this